C₁₉H₂₆O₂ · 286.41 g/mol
(−)-trans-Δ9-Tetrahydrocannabivarin
CB1 antagonist at low doses — appetite suppression, metabolic effects, anti-diabetic
Tetrahydrocannabivarin is a propyl homologue of THC — structurally similar but with a 3-carbon side chain instead of THC's 5-carbon chain. This structural difference produces dramatically different pharmacology: at low doses, THCV acts as a CB1 receptor antagonist (blocking THC's effects), while at high doses it may act as a partial agonist. THCV suppresses appetite, reduces body weight, and improves insulin sensitivity in animal models, making it one of the most promising cannabinoids for metabolic disease research.
Studies Indexed
280+
Half-Life
Not well characterized
Primary Receptors
CB1 (antagonist/partial agonist dose-dependent), CB2 (partial agonist)
Last Updated
June 2026
THCV is found in significant concentrations primarily in African sativa cannabis strains, particularly from South Africa, Nigeria, and Afghanistan. It is present in most cannabis strains at low levels (<1%) but can reach 16% in some African varieties. THCV's unique pharmacology stems from its shorter side chain: at low doses (below ~5mg in humans), it acts as a neutral CB1 antagonist, blocking THC's psychoactive effects and suppressing appetite. At higher doses, it may produce mild psychoactive effects as a partial agonist. THCV also activates CB2 receptors and TRPV1 channels. The most clinically significant findings are in metabolic disease: THCV reduces body weight, improves insulin sensitivity, and reduces fasting plasma glucose in obese mice — effects that have led to Phase II clinical trials in type 2 diabetes. THCV also shows anticonvulsant properties and may reduce anxiety without the appetite suppression seen with CB1 antagonists like rimonabant.
Evidence-rated summary of clinical and preclinical research by condition.
THCV improved insulin sensitivity, reduced fasting glucose, and reduced body weight in obese mouse models. A Phase II trial (GW Pharmaceuticals) showed THCV improved fasting plasma glucose and adiponectin levels in type 2 diabetes patients.
THCV suppresses appetite and reduces body weight in animal models via CB1 antagonism, without the psychiatric side effects of rimonabant. Potential as a weight management agent.
THCV showed anticonvulsant effects in multiple mouse seizure models, including models of Dravet syndrome. May act synergistically with CBD.
THCV reduced anxiety in conditioned fear models without suppressing the fear response entirely, suggesting potential for PTSD treatment. Mechanism may involve CB1 antagonism in the amygdala.
THCV showed neuroprotective effects in a mouse model of Parkinson's disease, reducing dopaminergic neuron loss and improving motor function via CB2 activation.
Peer-reviewed research with DOI links
Cascio MG, Gauson LA, Stevenson LA, et al.
British Journal of Pharmacology
Characterized THCV's pharmacological profile at CB1, CB2, and 5-HT1A receptors, demonstrating its neutral CB1 antagonism at low doses and partial agonism at high doses.
DOI: 10.1111/j.1476-5381.2009.00420.xJadoon KA, Ratcliffe SH, Barrett DA, et al.
Diabetes Care
Randomized, double-blind, placebo-controlled trial showing THCV significantly improved fasting plasma glucose and adiponectin levels in type 2 diabetes patients, supporting its development as an anti-diabetic agent.
DOI: 10.2337/dc16-0650Known interactions with pharmaceutical drugs. Consult a healthcare provider before combining. Full interactions database →
| Drug / Class | Severity | Mechanism | Clinical Effect |
|---|---|---|---|
| THC | moderate | CB1 antagonism at low doses blocks THC psychoactivity | THCV may reduce or block THC's psychoactive effects at low doses; at high doses, additive effects possible |
| Antidiabetic medications (metformin, insulin) | moderate | Additive glucose-lowering effects | Potential for additive hypoglycemia — monitor blood glucose carefully |
| CB1 antagonists (rimonabant) | moderate | Additive CB1 antagonism | Additive appetite suppression and potential psychiatric effects |
Critical questions that remain unanswered in the current literature — representing the frontier of THCV (Tetrahydrocannabivarin) research.
Explore the clinical and preclinical evidence for THCV (Tetrahydrocannabivarin) across these therapeutic areas.
